2023年8月7日

分享這篇文章提供的新聞突破2023 ASCO年會上公布的新數據紐約,8月7日,2023年Leal從衛生(“誠實的”或“公司”),原名Trialjectory AI-powered治療決策支持平台,把病人獲得先進的癌症治療和使製藥和生物技術行業成規執行臨床試驗,今天宣布,該公司提出了一個海報在今年的美國臨床腫瘤學會年會(ASCO)突破,展示的影響病人的ECOG評分在固體和non-solid腫瘤臨床試驗資格。的海報是莉娜Lapidot博士,RD, Leal健康醫學主任。東部合作腫瘤組(ECOG)分數表明患者的殘疾程度通過0 - 5(0表示完全活躍的病人,而5代表死去的病人),是一種常見的資格標準用來評估患者臨床試驗登記。雖然過去製藥公司開發和執行臨床試驗招募病人(即在相對良好的身體條件。,minimal comorbidities and with a favorable ECOG performance status), many cancer patients have significant disabilities, leading to higher ECOG scores and resulting in their exclusion from clinical trials. Therefore, the strict threshold of ECOG scores for trials results in a skewed representation of real-world patients while also creating massive barriers to enrollment for patients. Leal's study evaluated the impact of ECOG scores on solid and non-solid tumor clinical trial eligibility. The Company assessed patients on Leal's AI-powered platform and reviewed their self-reported questionnaires, which are the basis for patients' clinical profiles. These profiles include unique factors relevant to clinical trial eligibility, including disease status, stage, biomarkers, treatment history, comorbidities and demographics. To assess the impact of patients' ECOG scores, Leal adjusted the dataset to reflect a better ECOG score per patient while all other parameters remained constant. Key findings include: In a dataset of 5,018 patients, those with higher ECOG scores (2 or 3) were matched to significantly fewer clinical trials, negatively impacting patients' trial options. Modifying patient ECOG scores from 3 to 2 and from 2 to 1 led to overall increases of 246 percent and 189 percent in matched clinical trials for all cancer types, respectively. The prevalence of clinical trials that allow for worse ECOG scores (2 or higher) was significantly higher for patients with non-solid tumors compared to solid tumor trials. As a result, improving patient ECOG scores proved to be more beneficial for patients with solid tumors compared to those with non-solid tumors. "Our findings show that a patient's cancer type may influence the relationship between ECOG scores and access to clinical trials," said Dr. Lapidot. "Adjusting ECOG scores for the better appears to have a greater impact on trial eligibility for patients with solid tumors, as these patients may face more barriers to enrollment due to strict ECOG requirements. Using ECOG scores as a strict criterion for enrolling patients in clinical studies is outdated and detrimental, and we need to ensure that real-world cancer patients are represented. A more nuanced approach is needed to take into account the specific cancer type and its associated physical demands. Leal's mission is to continue identifying any limiting criterion in clinical trial design as a way to raise awareness of how these factors can impact patient recruitment and access to lifesaving treatment." About Leal Health Leal Health , formerly known as Trialjectory, is a patient-first, AI-powered treatment decision support platform dedicated to improving cancer care. Working directly with patients, healthcare providers and pharmaceutical companies, Leal democratizes access to advanced cancer treatment and empowers the pharmaceutical and biotech industry to execute patient-centric clinical trials. The Company has been recognized by TIME as one of " The 100 Best Inventions of 2020 " and named an honoree in the AI and data category for Fast Company's " 2021 World-Changing Ideas Awards ." For more information, please visit www.leal.health , and follow the Company on Facebook and LinkedIn . SOURCE Leal Health